Code to support
Evaluation of Circulating Plasma Proteins in Breast Cancer: A Mendelian Randomisation Analysis
Anders Mälarstig1,2, Felix Grassmann1,3, Leo Dahl4, Marios Dimitriou1,2, Dianna McLeod1, Marike Gabrielson1, Karl Smith-Byrne5, Cecilia E. Thomas4, Tzu-Hsuan Huang6, Simon KG Forsberg7, Per Eriksson7, Mikael Ulfstedt7, Mattias Johansson8, Aleksandr V. Sokolov9, Helgi B. Schiöth9, Per Hall1, 10, Jochen M. Schwenk4, Kamila Czene1, Åsa K. Hedman1,2
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
- Pfizer Worldwide Research Development and Medical, Stockholm, Sweden
- Institute of Clinical Research and Systems Medicine, Health and Medical University, Potsdam, Germany
- Science for Life Laboratory, Department of Protein Science, KTH Royal Institute of Technology, Solna, Sweden
- Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford
- Cancer Immunology Discovery, Pfizer Inc., San Diego, California
- Olink Proteomics AB, Uppsala, Sweden
- Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France
- Department of Surgical Sciences, Functional Pharmacology and Neuroscience, Uppsala University, Uppsala, Sweden.
- Department of Oncology, Södersjukhuset, Stockholm, Sweden
Corresponding author:
Anders Malarstig, Ph.D.,
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet
Nobels väg 12A
171 65 Stockholm, Sweden
Phone: +46 (0) 8-55052514 E-mails: anders.malarstig@ki.se, anders.malarstig@pfizer.com